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Abstract
Mycobacterium tuberculosis is assumed to remain in a quiescent state during latent infection, being unable to grow in culture. The aim of
this study was to evaluate the detection of viable but non-cultivable bacilli with metabolic activity in human clinical samples using a pro-
cedure that is independent of the immunological status of the patient. The study was performed on 66 human clinical samples, from
patients subjected to routine diagnosis to rule out a mycobacterial infection. Specimens from pulmonary and extra-pulmonary origins
were veriﬁed to contain human DNA before testing for M. tuberculosis DNA, rRNA and transient RNA by real-time quantitative PCR.
Clinical records of 55 patients were also reviewed. We were able to detect viable but non-cultivable bacilli with a metabolic activity in
both pulmonary and extra-pulmonary samples. Mycobacterium tuberculosis RNA was detected in the majority of culture-positive samples
whereas it was detected in one-third of culture-negative samples, 20% of them showed metabolic activity. Ampliﬁcations of the ftsZ
gene and particularly of the main promoter of the ribosomal operon rrnA, namely PCL1, seem to be good targets to detect active bacilli
putatively involved in latent infection. Moreover, this last target would provide information on the basal metabolic activity of the bacilli
detected.
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Introduction
Tuberculosis (TB) is a granulomatous disease caused by the
infection by Mycobacterium tuberculosis. The resurgence of TB
and its importance as a worldwide cause of morbidity and
mortality have focused attention on the need for more rapid
and reliable diagnostic procedures [1].
Following infection by the tubercle bacilli progression to
disease depends on the ability of the immune system of the
patient to resist the pathogen [2]. TB is a disease with com-
plex pathogenic mechanisms, the lung being the main tissue
targeted by the infection. However, albeit at a lower fre-
quency, the disease can also affect extra-pulmonary tissues
where TB is usually more difﬁcult to diagnose, mainly
because of unspeciﬁc symptoms and technical difﬁculties in
isolating the bacteria as well as a lower bacillary load [3].
The bacilli, once inside the human host, can cause either a
latent disease (about 90% of cases) or an active disease
(about 10% of cases), a condition that may also result from
the progression of the endogenous reactivation of a latent
infection.
Latent TB infection (LTBI) is a state characterized by the
presence of a persistent immune response, with absence of
symptoms or signs of the disease [4]. Although the clinical
deﬁnition of LTBI appears clear, the state of the bacteria in
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such a condition is poorly characterized [5–7]. The metabolic
state of the M. tuberculosis during latent infection remains to
be characterized and, to date, it is not possible to determine
if the bacilli are alive in these circumstances [4]. Traditionally,
latent TB is supposed to be caused by viable but non-cultiva-
ble bacilli [8] that remain quiescent in the lung granulomas.
However, new data indicate that M. tuberculosis DNA can be
detected in tissues without granulomas [9,10], and the recent
dynamic hypothesis of LTBI suggests that the quiescent bacilli
may be spread out from the granulomas during latency [11].
This is in accordance with the recent consideration of
M. tuberculosis infection as a continuous spectrum extending
from sterilizing immunity to clinical disease [12].
An LTBI is usually diagnosed by a tuberculin skin test
(TST), which has been used for more than a century. How-
ever, bacillus Calmette–Gue´rin vaccinations [13], repeated
TST, exposure to other mycobacteria and immunodeﬁcien-
cies limit the efﬁcacy of TST. New diagnostic tools were
developed for latent infections, including in vitro tests to
detect speciﬁc cell-mediated immune responses against
M. tuberculosis (interferon-c release assays), that overcome
some of the limitations of TST [14,15]. However, the differ-
entiation between latent and active TB remains difﬁcult [4].
Diagnostic assays based on nucleic acid ampliﬁcation meth-
ods, including PCR, are currently used for a rapid TB diagno-
sis. However, their usefulness for LTBI diagnosis remains
uncertain [16].
The purpose of this study was to evaluate the detection
of viable but non-cultivable bacilli with metabolic activity
through detection of bacterial transient RNA in clinical
samples that were negative for M. tuberculosis by using stan-
dard microbiological diagnostic procedures. Furthermore,
we aimed to develop a procedure of identiﬁcation of LTBI
that was independent of the immunological status of the
patient. To this end, we performed quantitative reverse
transcription PCR (qRT-PCR) to detect the presence of
bacterial RNA in both pulmonary and extra-pulmonary clini-
cal samples.
Materials and Methods
Design of the study
From February 2006 to June 2008, a total of 103 samples
from 90 patients were collected in the laboratories of Hospi-
tal Doce de Octubre and Fundacion Jimenez Diaz in Madrid
(Spain). Samples were collected from individuals suspected of
having mycobacterial disease. Most of the biopsies were sent
for mycobacterial culture following the Hospital protocols,
regardless of the suspicion of mycobacterioses.
Clinical records were studied retrospectively. Data con-
sidered as putatively related to a mycobacterial infection
were collected that included immune status; previous or
actual cancer; fever; previous history of TB or contact with
TB patients; TST results; and symptoms and signs related to
TB.
The study was approved by the Ethical Committees for
Clinical Research of the hospitals where the samples were
processed.
Microbiological analysis
After standard procedures of decontamination with N-acetyl-
cysteine-NaOH, the samples were inoculated in liquid media
(BacT-Alert (BioMe´rieux, Marcy l’Etoile, France) or MGIT
(Becton Dickinson, Franklin Lakes, NJ, USA) according to
the Hospital) and solid media (Lo¨westein–Jensen and Colet-
sos; BioMe´rieux). Cultures were considered negative when
no growth was detected after 45 days at 37C in liquid
media or after 8 weeks in solid media. Positive cultures were
conﬁrmed by acid-fast ﬂuorescent stain. Mycobacteria were
identiﬁed using standard tests including speciﬁc molecular
probes (AccuProbe; GenProbe, San Diego, CA, USA).
Total nucleic acid isolation
Aliquots were collected directly from decontaminated sam-
ples, after reception in both clinical microbiology laborato-
ries, in Eppendorf tubes containing guanidium chloride
(Merck, Whitehouse Station, NJ, USA) and glass beads (150–
212 mm; Sigma, St Louis, MO, USA) and maintained frozen
at )70C until required.
Samples were defrosted and mechanically lysed with Fast
Prep (Bio101 Savant), using seven pulses at maximum speed,
with 2 min on ice after each pulse. Lysates were extracted
once with phenol–chloroform–isoamyl alcohol (25:24:1), fol-
lowed by three extractions with chloroform–isoamyl alcohol
(24:1) [17]. The supernatant was ethanol precipitated over-
night at )70C. After high-speed centrifugation, sediments
were resuspended in 20 lL H2O dyethyl pyrocarbonate and
10 lL were used for direct detection of human and bacterial
DNA. The remaining 10 lL was reverse-transcribed to
40 lL of cDNA using random primers (Promega, Madison,
WI, USA) and Superscript III (Promega). DNAse treatment
was not performed to avoid the loss of the material through
further puriﬁcations.
Quantitative PCR
Quantitative PCR was performed using a capillary Light
Cycler real-time ampliﬁer and SYBR Green as ﬂuorescent
label (Roche, Indianapolis, IN, USA) using primers described
in Table 1. LightCycler Fast Start DNA master SYBR Green I
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reagent (1 lL) was supplemented with 3.5 mM MgCl2 (ﬁnal
concentration) and 0.5 lM of each primer in a 7 lL volume.
Sample (3 lL) was added to the mix. PCR cycling pro-
gramme: denaturation, one cycle of 95C for 10 min with a
transition rate of 20C/s; ampliﬁcation, 45 cycles at 95C for
0 s, the annealing temperature (Table 1) of each primer for
5 s and an extension step at 72C for 10 s with a single ﬂuo-
rescence acquisition. Speciﬁcity of the reaction was veriﬁed
by analysis of the melting curve and by agarose gel electro-
phoresis of the ﬁnal ampliﬁed product. Cross-contamination
was ruled out using standard manipulation procedures of
control.
An arbitrary threshold was set at position one of the log
of ﬂuorescence level versus cycle number plot. The Ct value
is deﬁned as the cycle number at which the ﬂuorescent level
crosses this threshold. Only those samples with Ct value in
the upper limit of detection in the Light Cycler system (100
copies of M. tuberculosis H37Rv genome equivalent corre-
sponding to 0.5 pg) were considered positive.
Targets analysed by quantitative PCR
Only the samples that ampliﬁed the b-globin eukaryotic gene
[18] were tested for the presence of bacterial nucleic acids.
Presence of M. tuberculosis DNA in the samples was deter-
mined by detection of IS6110 [19] a multi-copy target of this
bacterium. These values were used to evaluate the potential
bacterial DNA contamination in the cDNA. To do so, ten
copies of the IS6110 were considered as a mean value that
was subtracted from the amount of cDNA obtained in the
corresponding sample.
Four transcripts were ampliﬁed in the cDNA: 16S rRNA
[20]; rrnA-PCL1 [21]; ftsZ gene [22]; and hspX gene [22].
Targets and primers (Roche) used for the ampliﬁcations are
summarized in Table 1. All primers are speciﬁc for M. tuber-
culosis, except for 16S rRNA which are common for all
mycobacteria. Each of the cDNA ampliﬁcations was per-
formed in duplicate.
Results
Detection performances in the samples using quantitative
PCR
In all, 103 specimens were collected including a higher num-
ber of samples from extra-pulmonary (58) than from pulmo-
nary (45) origins. All samples were tested for the presence
of eukaryotic DNA by qPCR. Thirty-seven samples did not
amplify that target, probably because of the presence of PCR
inhibitors. Other unknown problems may have occurred as a
result of the unplanned collection or during the manipulation
of the samples. The 66 samples positive for human DNA
were then studied to detect the presence of M. tuberculosis
DNA and RNA (Table 2). Complete data are summarized in
Supplementary material, Table S1.
The bacterial IS6110 was detected in 19 samples and
mycobacterial cDNA was ampliﬁed from 35 samples
(Table 2). As expected, cDNA was detected in a higher
number of samples than DNA (Table 2).
Table 3 shows the PCR results according to the anatomi-
cal origin of the samples and culture results. The M. tubercu-
losis nucleic acids were detected in over 75% of culture
positive samples and over 17% of culture negative samples.
Mycobacterial nucleic acids were found in culture negative
samples from both pulmonary and extra-pulmonary samples.
Mycobacterium tuberculosis cDNA was ampliﬁed in 30.2% of
the culture negative samples (16/53), including 20.8% of
samples carrying bacilli with evidence of transient RNA activ-
ity (11/53) (Table 3).
TABLE 1. Targets, primers and conditions used in real-time
quantitative PCR
Targets Primer name and sequence (5¢ – 3¢)
Ann.
temp.
(C)a Sizeb
b-globin GH20—5GAAGAGCCAAGGACAGGTAC3 60 268
PCO4—5CAACTTCATCCACGTTCACC3
IS6110 IS-1—5CCTGCGAGCGTAGGCGTCGG3 68 123
IS-2—5CTCGTCCAGCGCCGCTTCGG3
16S rRNA 16S-F—5ATGACGGCCTTCGGGTTGTA3 66 120
RAC-7—5CGTATTACCGCGGCTGCTGGCAC3
rrnA-PCL1 PCL1TB-F—5TGTGTTTGGTGGTTTCACATT3 60 120
PCL1TB-R—5GGAAAAGGGAGCCAAAGGTA3
ftsZ 835RL-810FU—5GCAGCGACTTGGGCTTGTTC3 62 71
835RL—5GGGTGAGCGGCGTCTTGTAC3
hspX 268FL-283RU—5AGCAGAAGGACTTCGACGGTC3 64 60
268FL—5GTGCGAACGAAGGAACCGTA3
aAnnealing temperature for each primer set.
bThe size of the amplicons is indicated in base pairs.
TABLE 2. Detection of mycobacterial nucleic acids in b-glo-
bin-positive clinical samples
Samples Number
DNA RNA
IS6110
16SrRNA
only
Any
target
Total
RNA
Pulmonary
Culture-positive 8 5 (62.5) 0 7 7 (87.5)
Culture-negative 20 6 (30) 5 2 7 (35)
Extra-pulmonary
Culture-positive 5 5 (100) 1 4 5 (100)
Culture-negative 33 3 (9.1) 7 [NTM] 9 16 (48.5)
Total
Culture-positive 13 10 (76.9) 1 11 12 (92.3)
Culture-negative 53 9 (17) 5 11 23 (43.4)
Number of PCR-positive samples. Percentages corresponding to total values of
each (culture-positive, culture-negative and total samples) are indicated in paren-
theses (%).
Seven extra-pulmonary culture-negative samples that were PCR-negative for
mycobacterial DNA and ampliﬁed 16SrRNA as single RNA target were consid-
ered to represent detection of non-tuberculous mycobacteria and were labelled
as [NTM].
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The 16S rRNA was detected as the single mycobacterial tar-
get only in culture-negative extra-pulmonary samples (Table 3).
The seven culture-negative samples amplifying 16S rRNA as the
unique target were considered as putative non-tuberculous
mycobacteria carriers (indicated as [NTM] in Table 3) and were
not included in the viable but non-cultivable analysis presented
in the rightmost column of Table 3. Non-tuberculous mycobac-
teria were conﬁrmed by sequencing of the 16SrRNA in three of
these samples (data not shown). That detection in extra-pulmo-
nary samples agreed with previous publications [23,24].
The comparison of the detection of cDNA according to
the transcripts ampliﬁed showed, as expected, that all but
one culture-positive sample was ampliﬁed whereas only one-
third of the culture-negative samples were ampliﬁed
(Table 4). Transcripts involved in the active growth of the
bacteria (PCL1 and ftsZ) were more frequently ampliﬁed in
culture-positive samples, indicating the presence of actively
dividing bacilli. The 16S rRNA was most frequently detected
in culture-negative samples (Table 4).
Baseline characteristics of the patients
The specimens studied were collected from 66 different sub-
jects, but only 55 clinical records could be reviewed. Data
are summarized in Supplementary material, Table S1.
A TST was recorded in only 14 patients and ﬁve had posi-
tive results. Three of these TST-positive patients had cul-
ture-positive samples and were diagnosed with TB,
M. tuberculosis RNA was detected in two of them. Samples
from the two other TST-positive patients were culture-nega-
tive and M. tuberculosis RNA was not detected (Table S1).
The TST-negative patients also had culture-negative samples
and a single transcript was detected in two of them, corre-
sponding to IS6110 and 16S rRNA, respectively.
Data from the clinical records, putatively related to a
mycobacterial infection, were identiﬁed in 30 patients with
culture-negative samples. Samples from six of these 30
patients ampliﬁed M. tuberculosis-speciﬁc targets and two
additional patients belonged to the putative non-tuberculous
mycobacteria carriers (Table S1).
Discussion
We studied the presence of M. tuberculosis with metabolic
activity in culture-negative samples from those received for
routine diagnosis from two different hospitals. No selection
criteria of the samples were established, allowing the collec-
tion of pulmonary and extra-pulmonary specimens. Only the
TABLE 3. Detection of mycobacterial nucleic acids in b-globin-positive clinical samples according to the anatomical origin
Samples Culturea +/)
DNA RNA
IS6110 16SrRNA only Any target Mtb VBNCb
Sputum (n = 9) 8/1 5/1 0/0 7/1 1
Bronchial (n = 17) 0/17 0/5 0/5 0/1 6
Other (n = 2)c 0/2 0/0 0/0 0/0 0
Total pulmonary (n = 28)d 8/20 5 (62.5)/6 (30) 0/5 (25 7 (87.5)/2 (10) 7 (35)
Adenopathy (n = 6) 3/3 3/0 1/1 [NTM]c 2/1 1
Liquids (n = 6)f 0/6 0/0 0/1 [NTM] 0/3 3
Pleura (n = 8) 1/7 1/1 0/0 1/0 0
Synovia (n = 5) 0/5 0/0 0/2 [NTM] 0/1 1
Otherg (n = 13) 1/12 1/2 0/3 [NTM] 1/4 4
Total extra-pulmonary (n = 38)d 5/33 5 (100)/3 (9.1) 1 (20)/7 [NTM] (21.2) 4 (80)/9 (27.3) 9 (27.3)
Total samples (n = 66) 13/53 10 (77)/9 (17) 1 (7.7)/12 (22.6) 11 (84.6)/11 (20.8) 16 (30.2)h
aNumber of samples that were culture-positive (+) or culture-negative (–) are indicated as +/–.
bNumber of samples culture-negative and PCR-positive for Mycobacterium tuberculosis (Mtb) RNA (viable but non-cultivable, VBNC).
cOther pulmonary samples: one biopsy; one abscess.
dTotal results globally and for pulmonary and extra-pulmonary samples are indicated. Percentages corresponding to total values of each (culture-positive or culture-negative)
are indicated in parentheses (%).
eSamples negative for IS6110 and positive for 16SrRNA as single target were considered to represent non-tuberculous mycobacteria [NTM].
fLiquid extra-pulmonary samples: three urine; three cerebrospinal ﬂuid.
gOther extra-pulmonary samples: nine biopsies; two abscesses.
hThis value includes ﬁve pulmonary culture-negative samples that ampliﬁed 16SrRNA as single RNA mycobacterial target and also ampliﬁed M. tuberculosis DNA, therefore
they were not considered to carry non-tuberculous mycobacteria. The value corresponds to 22.7% of the total setting.
TABLE 4. Detection of mycobacterial RNA in b-globin-positive clinical samples according to the targets studied
Culture 16SrRNA rrnAPCL1 ftsZ hspX PCR+ samples
Positive (n = 13) 7 (53.8) 11 (84.6) 10 (77) 6 (46.1) 12 (92.3)
Negative (n = 53) 11 (20.8) 7 [NTM] (13.2) 9 (17) 5 (9.4) 5 (9.4) 16 (30.2) 7 [NTM] (13.2)
Total (n = 66) 25 (37.9) 20 (30.3) 15 (22.7) 11 (16.7) 28 (42.4)
Number of samples qRT-PCR positive. Percentages corresponding to total values of each (culture-positive or culture-negative) are indicated in parentheses (%).
[NTM], non-tuberculous mycobacteria.
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samples amplifying eukaryotic DNA were then ampliﬁed to
detect the presence of mycobacterial DNA (qPCR) and
cDNA (qRT-PCR).
The detection of M. tuberculosis DNA in culture-negative
clinical samples was previously explained by the presence of
dead or non-viable bacilli [25]. However, the detection of
cDNA is considered as a conﬁrmation of the presence of
viable bacilli [26,27].
To obtain information about the metabolism of the bacilli
we aimed to detect the active synthesis of the ribosomal
RNA that reﬂects the basal metabolic activity of the cells
[28]. It is known that the stability of the pre-rRNA is similar
to that of other mRNA in the cell, being that the mature
16S rRNA is more stable probably because it is linked to
bacterial ribosomal proteins as part of the ribosomes [28].
This means that the detection of 16S rRNA may indicate
that the bacteria were alive, but their metabolic activity
could not be conﬁrmed at this step. For this reason, we
ampliﬁed the pre-rRNA product derived from the main ribo-
somal RNA promoter of M. tuberculosis, namely PCL1 [21],
as well as the mature product, the 16S rRNA. We detected
the presence of the 16S rRNA in 25 samples, including 18
culture-negative samples (Table 4). However, the detection
of other transcripts involved in the bacterial growth (such as
ftsZ and PCL1) was more frequent in culture-positive sam-
ples (Table 4). This is expected because of the physiological
role of the respective gene products. In seven of the culture-
negative samples that only ampliﬁed the 16S rRNA, IS6110
was not detected so they may have contained non-tubercu-
lous mycobacteria [24].
According to our results, bacilli putatively involved in LTBI
were detected in 30.2% of our culture-negative samples and
bacilli with metabolic activity were identiﬁed in 20.8% of
them from both pulmonary and extra-pulmonary origins
(Table 3).
Regarding the clinical impact of the qRT-PCR in TB diag-
nosis, the clinical records were available for 55 patients. All
patients with culture-positive samples showed clinical data
related to TB. Most of the patients with culture-negative
samples (30/47) had clinical data that might be related to a
mycobacterial infection. This was expected because the sam-
ples were collected from those received in the laboratories
usually following a clinical suspicion of mycobacterial infec-
tion. Unfortunately, ampliﬁcations were obtained at a similar
level in samples regardless of the clinical data related to
mycobacterial infection (Table S1).
These misleading results may be the result of the com-
plexity of clinical TB diagnosis, particularly when the infection
has an extra-pulmonary localization, which it occurs in more
than half of our samples.
The main limitation of our study was the number of sam-
ples available. However, this limitation may reinforce the
hypothesis that the number of samples containing viable but
non-cultivable bacilli may be increased in a controlled study.
Another limitation was that the level of DNA contaminat-
ing the cDNAs was unknown, and could only be approxi-
mated through the level of IS6110 detected (see Materials
and methods). We have no clear solution to solve this prob-
lem because it is recommended to avoid DNAse treatment
to minimize the loss of this scarce material during further
puriﬁcations.
Finally even though this is a rare event except for some
South Asian countries [29], the possibility of viable but non-
cultivable M. tuberculosis bacilli with a low or zero copy num-
ber of IS6110 in their genomes should also be considered.
Other IS multi-copy elements could be targeted instead for
DNA detection when these circumstances are suspected.
The detection of mycobacterial cDNA in pulmonary and
extra-pulmonary culture-negative samples agreed with previ-
ous data suggesting that M. tuberculosis may establish a latent
infection in both types of anatomical locations with or with-
out granulomas [8,9,30,31].
Concluding Remarks
According to our results, we suggest that the PCL1 pro-
moter of the rrnA operon of M. tuberculosis may be a target
of interest to detect viable and metabolically active bacilli in
culture-negative samples.
The advantages of this detection procedure to test for
LTBI would be to avoid the secondary effects that may be
observed with TST. Moreover, it would not be inﬂuenced
by the immune system state of the patient as observed
with TST and interferon-c release assays can be used
advantageously in children and can be performed on every
type of sample, of either pulmonary or extra-pulmonary
origin.
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